Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trop-2 Targeted PET Probes in Advanced TNBC
NCT07046455Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial in triple-negative breast cancer (TNBC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Correlation between 89Zr-DFO-hSR7 uptake in tumor lesions and TROP2 expression in breast cancer tissues at 36 months, Diagnostic efficacy of 89Zr-DFO-hSR7 and 18F-FDG in breast cancer lesions at 36 months and 3 more. Started Mar 2025; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07046455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046455.